Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Would you consider using acetazolamide to manage glomerular hyperfiltration in patients with type 1 diabetes, since SGLT2 inhibitors are contraindicated in this population?
Ginsburg C, et al, PMID 39466253
Related Questions
How do you approach counseling the family of a patient with advanced CKD and dementia when discussing the options and implications of starting dialysis?
Do you have a preference between an ACEI and ARB when initiating therapy for a patient with diabetic kidney disease, albuminuria, and hypertension?
Do you recommend avoiding SGLT2i use for patients with proteinuria from diabetic kidney disease if they have urinary retention requiring catheterization?
Do you advise your patients with CKD to consume a set amount of fluids daily in an attempt to prevent disease progression?
What are some practical tips for when a patient's consistently stated goals of care do not correlate with their actions?
Is there a role for early GLP-1 therapy for weight loss in patients with early-stage ADPKD and obesity, given the association between obesity and the risk of progression to ESKD?
Are there situations when you recommend initiating dialysis in patients with advanced chronic kidney disease, even if their symptoms are minimal and electrolytes are well controlled with medical management?
Would you recommend SGLT2 inhibitors for patients with sickle cell nephropathy and severely increased albuminuria despite the potential medication associated risk for vaso-occlusive crises?
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
Would you advocate for SGLT2 inhibitors if they are not fully covered by insurance in patients with moderately increased albuminuria (< 300 mg/g) who are on maximal dose ACEi/ARB?
